TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brainsway ( (BWAY) ) has shared an announcement.
On November 17, 2025, BrainsWay Ltd. announced the launch of a multicenter clinical trial for its Deep TMS 360 system aimed at treating Alcohol Use Disorder (AUD). This trial represents a significant milestone for the company as it explores the potential of its next-generation multichannel TMS technology to reduce heavy drinking and cravings in individuals with AUD. The study will involve over 200 participants across various U.S. and international sites, marking an important step in BrainsWay’s efforts to expand into new therapeutic areas and address major public health challenges.
The most recent analyst rating on (BWAY) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s robust balance sheet and improved cash flow generation enhance its financial stability. However, the high P/E ratio and absence of a dividend yield are concerns for valuation. Technical indicators suggest a positive trend, but potential oversold conditions warrant caution.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, which has received FDA clearance for indications such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to Deep TMS.
Average Trading Volume: 73,411
Technical Sentiment Signal: Buy
Current Market Cap: $317M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.